Cassava Bolts To Record High After Alzheimer's Drug Improves Cognition Cassava Sciences said Thursday its Alzheimer's treatment showed promise in a six-month study and SAVA stock bolted to a record high. Cassava Sciences ( SAVA ) said Thursday its Alzheimer's treatment showed promise in a six-month study and SAVA stock bolted to a record high. ------------------------- TP01 = 92,47000$ TP02 = 112,85000$ TP03 = 133,23000$ TP04 = 153,61000$ TP05 = 173,99000$
@Zantepenko, Yes, very normal, in order to make good profits .. The price rose due to a logical reason, which is a solution to a medical problem, and the results are promising in the future.
UnknownUnicorn4312102
⋅
@WsbGlobalTeam, How do you feel about it now after closing
WsbGlobalTeam
⋅
@RoscoeCruz, Very optimistic that the rise came through positive news, which is a solution to a medical problem and has a promising future .. This decline is expected to start from the bottom to achieve more of the deterioration and gain more financial flows for the company and provide the opportunity for investors to buy more shares ... The timing is very important. ... and time lines were set at which a decision would be taken. Now it is time to watch